CD&R and McKesson's $5.8B Option Care Health Buyout: Factor Attribution of Corporate-Sponsor Hybrid M&A, Healthcare Valuation Arbitrage, and Risk Spreads Across the Six-Factor Framework

Executive Summary: The Anatomy of a Hybrid Corporate-Sponsor Takeover

On October 6, 2026, institutional healthcare and special situations desks witnessed a landmark transaction restructuring the home infusion and specialty pharmacy sector. Clayton, Dubilier & Rice (CD&R) and McKesson Corporation (NYSE: MCK) entered into a definitive merger agreement to acquire Option Care Health, Inc. (NASDAQ: OPCH) for $32.05 per share in cash, representing an aggregate enterprise value of approximately$5.8 billion. The transaction price reflects a 37.1% premium over Option Care Health's undisturbed closing price of $23.38 on October 5, 2026, and values the enterprise at approximately 12.3x projected FY2026 Adjusted EBITDA.

The structure of the buyout marks a sophisticated departure from conventional leveraged buyouts (LBOs). Rather than a pure financial sponsor takeout or an outright corporate absorption, the acquiring consortium established a hybrid governance and capital architecture:

• Consortium Ownership Split: Private equity sponsor CD&R will hold an approximately 51% majority controlling interest, while strategic healthcare distributor McKesson will deploy approximately $1.4 billion in balance sheet cash to acquire an approximately 49% minority interest.
• Pre-Negotiated Call Framework: The agreement incorporates an explicit, condition-governed call framework establishing terms under which McKesson may subsequently acquire CD&R's 51% controlling interest, subject to specified performance hurdles and regulatory clearances.
• Financing Structure: CD&R Fund XII and McKesson delivered executed equity commitment letters totaling $2.873 billion. Critically, closing is not conditioned on third-party debt financing, eliminating the syndicated loan market execution contingency that derailed multiple healthcare sponsor transactions during the 2024–2025 rate shock.
• Accounting Treatment: McKesson will account for its 49% stake under the equity method of accounting, booking its proportional share of Option Care Health's net earnings into Other Income, net, preserving its investment-grade balance sheet leverage metrics.

For quantitative allocators, multi-asset desks, and risk arbitrageurs, this transaction serves as an empirical case study in factor convergence. It sits at the precise nexus of three structural market regimes:

1. The Cost-of-Capital Squeeze: With the 10-year US Treasury yield hovering at 5.28% and 30-year yields at 5.66%, standalone private equity sponsors face 8.5% to 9.5% unitranche borrowing costs. By partnering with an investment-grade corporate partner (McKesson, rated Baa1/A-), the sponsor synthetically lowers the consortium's weighted average cost of capital (WACC) while leaving debt-market capacity unexhausted.
2. Defensive Factor Inversion: As explored in our benchmark research on the Defensive Factor Paradox: Why Bond-Proxy Equities Fail During Stagflationary Rate Shocks, public healthcare providers have suffered severe duration multiple compression under elevated interest rates. Option Care Health's public equity traded at an optical discount despite generating resilient non-cyclical cash flows, exposing an arbitrageable divergence between public market multiples and private control values.
3. M&A Strategic Preemption: Similar to the corporate balance sheet dynamics analyzed in Schneider Electric's $22.6B PTC Takeover vs. 10% Stock Plunge, industrial and healthcare distributors are deploying cash flow windfalls to lock in proprietary infrastructure and specialty distribution channels ahead of anti-trust tightening.

This research brief decomposes the Option Care Health transaction across the proprietary Parallax Six-Factor Framework: Value, Quality, Momentum, Defensive, Size, and Tactical. We examine the mechanics of corporate-sponsor hybrid financing, model the risk arbitrage spread dynamics under 5.28% sovereign yields, and outline portfolio construction implications for healthcare sleeves and event-driven mandates.

---

Transaction Architecture & Capital Structure Mechanics

To evaluate the factor characteristics of the transaction, institutional investors must first inspect the legal and economic terms disclosed in the respective Form 8-K filings submitted by Option Care Health and McKesson on October 6, 2026.

Balance Sheet Decomposition & Valuation Metrics

Option Care Health operates as the largest independent US provider of home and alternate-site infusion services, employing over 5,000 clinicians across all 50 states. The company provides complex clinical therapies, including immunoglobulin (IVIG/SCIG), oncology infusions, parenteral nutrition, and heart failure inotropic therapies.

The transaction terms decompose as follows:

| Financial / Valuation Metric | Value / Term | Analytical Significance |
| :--- | :--- | :--- |
| Agreed Offer Price per Share | $32.05 Cash | 37.1$23.38) |
| Pre-Announcement Market Capitalization | $4.18 Billion | Fully diluted common shares of ~178.9M | | **Total Transaction Equity Value** |$5.73 Billion | Cash consideration for all outstanding common equity |
| Net Funded Debt (as of Q2 2026) | $1.08 Billion |$1.42B funded debt less $340M cash and equivalents | | **Total Enterprise Value (TEV)** |$5.81 Billion | TEV multiple of 12.3x FY2026E Adjusted EBITDA |
| CD&R Equity Commitment (Fund XII) | ~$1.47 Billion | ~51| **McKesson Cash Investment** | ~$1.40 Billion | ~49% minority equity ownership |
| Total Equity Commitment | $2.873 Billion | 49.5% equity check / 50.5% debt-and-rollover financing |
| Financing Conditionality | Zero | Fully committed equity backstop; no debt financing contingency |
| Target Closing Window | H1 2027 | ~6 to 9 months regulatory and shareholder approval timeline |

The Synthetic WACC Arbitrage

Under classical corporate finance theory, a pure private equity sponsor executing an LBO of a $5.8 billion enterprise under a 5.28% 10-year Treasury environment would confront severe interest coverage constraints:

$\text{Sponsor WACC} = \left(\frac{E}{V}\right) r_e + \left(\frac{D}{V}\right) r_d (1 - \tau_c)$

Assuming a typical 50/50 capital structure:

• Sponsor required equity return ($r_e$): $20.0\%$
• First-lien / syndicated debt rate ($r_d$): $\text{SOFR} (4.85\%) + 375 \text{ bps} = 8.60\%$
• Marginal corporate tax rate ($\tau_c$): $25.0\%$

$\text{Standalone Sponsor WACC} = (0.50 \times 20.0\%) + [0.50 \times 8.60\% \times (1 - 0.25)] = 10.00\% + 3.23\% = 13.23\%$

In contrast, McKesson finances its $1.4 billion minority equity check using retained operational cash flows and low-coupon commercial paper/senior notes:

• McKesson Cost of Equity ($r_{e,\text{MCK}}$): $\approx 8.50\%$ (Beta 0.58, ERP 4.25%, $R_f$ 5.28%)
• McKesson Pre-Tax Cost of Debt ($r_{d,\text{MCK}}$): $\approx 5.65\%$
• Blended Corporate WACC: $\approx 7.20\%$

By assembling a 51/49 consortium, CD&R effectively lowers the blended cost of capital across the equity stack. McKesson acts as a patient, strategic co-underwriter willing to accept an equity return hurdle significantly lower than a private equity hurdle ($8\%-10\%$ strategic hurdle vs. $20\%-25\%$ sponsor IRR), while securing a contractual option to acquire the remaining 51% stake at a later date. This corporate-sponsor hybrid model represents a structural innovation designed to navigate prolonged higher-for-longer interest rate regimes.

---

Factor Attribution Across the Parallax Six-Factor Framework

The Parallax Six-Factor Framework isolates systematic exposures to separate sustainable alpha from uncompensated style crowding. Below is the multi-factor decomposition of Option Care Health (OPCH) at the announcement of the acquisition.

+-------------------------------------------------------------------------------+
|          PARALLAX SIX-FACTOR PROFILE: OPTION CARE HEALTH (NASDAQ: OPCH)       |
|                      As of October 6, 2026 | Deal Price: $32.05               |
+-------------------------------------------------------------------------------+
| Factor Name   | Exposure (Z-Score) | Percentile Rank | Institutional Signal   |
+---------------+--------------------+-----------------+------------------------+
| 1. VALUE      | +1.28 (Deep Cheap) | 88th Percentile | Takeover Target Anchor |
| 2. QUALITY    | +0.94 (Robust FCF) | 79th Percentile | High-ROIC Asset Base   |
| 3. MOMENTUM   | +1.86 (Event Spike)| 96th Percentile | Sharp Breakout Surge   |
| 4. DEFENSIVE  | +1.12 (Low Beta)   | 84th Percentile | Non-Cyclical Demand    |
| 5. SIZE       | -0.42 (Mid-Cap)    | 36th Percentile | Sub-Scale Consolidation|
| 6. TACTICAL   | +1.45 (Arb Spread) | 91st Percentile | Merger Spread Carry    |
+-------------------------------------------------------------------------------+

1. The Value Factor: Public Market Disconnect vs. Private Control Multiples

Prior to the announcement, Option Care Health screened in the upper decile of healthcare Value factors, trading at 9.4x EV/EBITDA and a forward Price-to-Earnings ratio of 14.8x. This multiple reflected an unwarranted conglomerate discount imposed by public markets:

• The Specialty Infusion Disconnect: Public markets penalized OPCH throughout early 2026 due to general concerns over Medicare reimbursement pressure and Medicaid redeterminations. However, more than 75% of Option Care's therapy revenue is derived from commercial commercial payers, where demographic demand for home-administered biologic drugs continues to expand at 8% to 11% annually.
• Enterprise Free Cash Flow Yield: Over the trailing twelve months, OPCH generated $318 million in operating cash flow and incurred$84 million in maintenance capex, yielding $234 million in levered Free Cash Flow (FCF). At the undisturbed equity value of$4.18 billion, the stock offered a Free Cash Flow yield of 5.60%—exceeding the 10-year Treasury yield of 5.28% and marking it as a rare non-cyclical equity with positive sovereign carry.

As established in our research on Free Cash Flow Yield vs. Dividend Yield in Mature Compounding Franchises, companies that generate positive unlevered organic cash flows without relying on aggressive balance sheet debt become primary targets for corporate and sponsor acquisition when public valuations disconnect from asset replacement costs.

2. The Quality Factor: Cash Conversion and Capital Efficiency

Option Care Health exhibits high fundamental Quality factor characteristics that differentiate it from leveraged provider peers:

• Cash Conversion Cycle: The company converts over 70% of Adjusted EBITDA into pre-tax operating cash flow. Because home infusion avoids the massive real estate and hotel overhead of inpatient acute-care hospitals, tangible capital expenditure requirements remain low (under 2.0% of revenue).
• Return on Invested Capital (ROIC):

$\text{ROIC} = \frac{\text{NOPAT}}{\text{Invested Capital}} = \frac{\$355\text{M} \times (1 - 0.25)}{\$3.12\text{B}} \approx 8.53\%$

While headline ROIC appears moderate due to historical goodwill from the 2019 merger with BioScrip, cash return on tangible capital exceeds 28%. This underlying cash profitability provided CD&R and McKesson with the fundamental stability required to underwrite a $2.873 billion equity check without fearing operational cash burn.

3. The Momentum Factor: Regime Shift from Degradation to Event Catalyst

Over the 12-month period preceding October 5, 2026, Option Care Health exhibited negative price momentum (-18.4% relative to the S&P 500 Healthcare Index), driven by sector-wide multiple compression and lingering memory of its terminated 2023 merger agreement with Amedisys.

The merger announcement instantaneously triggered an event-driven momentum inflection:

• Price Gap: OPCH opened up 32.9% to $31.08, establishing a tight trading corridor within 3.1$32.05 cash offer price.
• Factor Re-Classification: The security transitioned instantaneously from a Distressed Momentum / Value Trap profile to an Event-Driven Low-Beta Fixed-Income Surrogate, altering its volatility and correlation structure within institutional multi-factor portfolios.

4. The Defensive Factor: Secular Aging vs. Sovereign Yield Competitor

Unlike traditional consumer staples companies that have suffered pricing power exhaustion—such as the dynamics analyzed in PepsiCo's 52-Week Low vs. 5.34% Yields—Option Care Health's defensive profile is underpinned by non-discretionary clinical demand. Patients receiving total parenteral nutrition or intravenous immunoglobulin cannot postpone or reduce dosage in response to macroeconomic stagflation.

Furthermore, home infusion delivers a massive structural cost savings to payors: treating a patient in the home setting costs between $150 and$300 per day, compared to $1,500 to$3,500 per day in an acute care hospital bed. Consequently, private insurers and Medicare Advantage plans systematically steer volume toward alternate-site infusion providers. This non-cyclical volume tailwind provides genuine defensive ballast that does not rely on price increases.

5. The Size Factor: Mid-Cap Vulnerability to Public Scale Disadvantages

With a market capitalization of $4.2 billion, Option Care Health occupied a challenging mid-cap tier in public equity markets. Mid-cap healthcare companies face disproportionate public compliance costs, lower sell-side coverage, and limited liquidity from mega-cap passive index funds.

By combining Option Care Health with McKesson's massive specialty distribution network (which supplies oncology clinics, physician practices, and hospital networks), the combined entity achieves institutional scale advantages that Option Care could not capture as a standalone publicly traded mid-cap entity.

6. The Tactical Factor: Risk Arbitrage Spread Decomposition

On October 6, 2026, following the announcement, Option Care Health traded at $31.12 per share against the$32.05 cash offer price, leaving a gross spread of $0.93 per share, or 2.99% (299 basis points).

To determine whether this spread offers an attractive tactical annualized return, risk arbitrage desks must model the timeline and completion probability:

$\text{Annualized Arbitrage Return } (R_{\text{ann}}) = \left( \frac{\text{Offer Price}}{\text{Current Market Price}} \right)^{\frac{365}{T}} - 1$

Assuming a targeted completion date of May 15, 2027 (221 days from announcement):

$R_{\text{ann}} = \left( \frac{32.05}{31.12} \right)^{\frac{365}{221}} - 1 = (1.02988)^{1.6516} - 1 \approx 4.98\%$

At an annualized return of 4.98%, the merger spread trades at an optical discount to the 10-year US Treasury yield (5.28%) and the 6-month Treasury bill (5.18%). This pricing reflects an institutional reality: under a 5.25%+ cash rate regime, risk arbitrage spreads below 6.00% annualized represent negative real risk premia.

+-------------------------------------------------------------------------------+
|                      RISK ARBITRAGE RETURN SPREAD MATRIX                      |
|                     Target: $32.05 | Current Close: $31.12                    |
+----------------------+--------------------+--------------------+--------------+
| Closing Date Window  | Days to Close (T)  | Annualized Return  | Spread vs T-Bill |
+----------------------+--------------------+--------------------+--------------+
| March 31, 2027 (Fast)| 176 Days           | +6.31%             | +113 bps     |
| May 15, 2027 (Base)  | 221 Days           | +4.98%             | -20 bps      |
| June 30, 2027 (Slow) | 267 Days           | +4.11%             | -107 bps     |
+----------------------+--------------------+--------------------+--------------+

Because the base case annualized return (-20 bps vs. T-bills) fails to compensate for regulatory duration risk, arbitrage capital will only enter aggressively if the spread widens toward $30.40–$30.70 (gross spread 4.4%–5.4%, yielding 7.5%–9.0% annualized).

---

Regulatory and Antitrust Risk Assessment: The FTC & DOJ Landscape

The critical determinant of deal completion is regulatory scrutiny under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. The Federal Trade Commission (FTC) and the Department of Justice (DOJ) have intensified enforcement across healthcare consolidation, specifically targeting vertical integration and private equity roll-ups.

1. Vertical vs. Horizontal Overlap Analysis

A pivotal structural attribute of this consortium is that it mitigates direct horizontal concentration:

• CD&R's Portfolio: CD&R does not currently own a competing national home infusion provider, eliminating direct local-market concentration issues that would trigger horizontal market-share divestitures.
• McKesson's Position: McKesson is primarily a pharmaceutical distributor, wholesaler, and oncology practice manager (US Oncology Network). It does not own a dominant competing home infusion pharmacy network. While vertical theories of harm exist (e.g., whether McKesson could disadvantage rival infusion providers by manipulating specialty drug distribution pricing), behavioral commitments and firewalls typically resolve these concerns without blocking transactions.

2. The 51/49 Minority Structuring Rationale

The decision to structure McKesson's initial investment as a 49% minority stake held alongside CD&R's 51% controlling interest was explicitly designed to address antitrust friction:

1. Direct Operational Independence: Option Care Health will remain a legally separate operating entity governed by its own independent management team, preventing immediate operational consolidation with McKesson's wholesale enterprise.
2. Delayed Acquisition Call: The framework granting McKesson the right to acquire CD&R's 51% stake in the future allows the parties to stagger regulatory review. The consortium can demonstrate to the FTC that market competition is preserved during the multi-year operating period following the initial transaction.
3. Absence of Debt Financing Condition: Section 6 of the Merger Agreement explicitly specifies that parent obligations are not conditioned on obtaining external debt financing. If private credit markets experience volatility, CD&R and McKesson remain legally bound to fund the purchase price using their committed equity lines.

---

Portfolio Construction & Implementation Framework

For chief investment officers, multi-asset managers, and healthcare analysts, the Option Care Health buyout provides actionable portfolio construction takeaways across three mandate types:

+---------------------------------------------------------------------------------------------------+
|                        INSTITUTIONAL ALLOCATION DECISION BLUEPRINT                                |
+---------------------------------------------------------------------------------------------------+
| Mandate Type              | Recommended Strategic Action      | Key Execution Parameters          |
+---------------------------+-----------------------------------+-----------------------------------+
| Core Healthcare Sleeves   | Reallocate Capital to Pure Quality| Rotate proceeds to MCK or CAH;    |
|                           |                                   | avoid reinvesting in levered peers|
| Event-Driven / Arbitrage  | Limit Exposure Unless Spread Widen| Set entry limit at < $30.75       |
|                           |                                   | to guarantee > 7.5% annualized IRR|
| Private Equity Allocations| Model Hybrid Co-Investment Models | Utilize corporate strategic co-sponsors|
|                           |                                   | to lower overall equity check size|
| Defensive Multi-Asset     | Replace Low-Beta Equity with Bills| Rebalance into 6-month T-Bills    |
|                           |                                   | yielding 5.18% with zero beta risk|
+---------------------------------------------------------------------------------------------------+

1. Healthcare Sleeve Rebalancing: Capital Rotation Strategy

For managers holding Option Care Health in long-only healthcare portfolios:

• Tender vs. Early Liquidation: With OPCH trading at $31.12 (within 3.0$32.05 cash tender), the stock's remaining upside is strictly capped. In an environment where 3-month Treasury bills yield 5.18%, holding the stock for the remaining 200+ days until closing introduces regulatory duration drag.
• Capital Rotation Candidates: Liquidate OPCH positions above $31.10 and redeploy capital into:
  1. McKesson Corporation (NYSE: MCK): Acquires a strategic 49% stake in the premier home infusion platform at an attractive 12.3x EBITDA multiple, accelerating its expansion into high-margin specialty pharmaceutical services without diluting its balance sheet.
  2. Cardinal Health (NYSE: CAH) or Cencora (NYSE: COR): Competing distributors that trade at compelling free cash flow yields and may pursue corresponding tuck-in acquisitions in ambulatory care.

2. Risk Arbitrage Mandates: Position Sizing and Hedges

For event-driven and merger arbitrage funds:

• Spread Thresholding: Under prevailing 5.28% benchmark Treasury yields, the hurdle rate for unlevered risk arbitrage is significantly higher than during ZIRP regimes. We recommend establishing a strict maximum purchase price of $30.75. At or below$30.75, the gross spread widens to 4.23%, producing an annualized return of 7.05% against an assumed 221-day timeline—providing a 187 bps premium over cash.
• Break Spread Downside Calculation: If the transaction were terminated due to regulatory intervention or shareholder dissent, OPCH's downside price would likely settle near its unaffected pre-announcement level of $23.38, implying a downside loss of -$7.74 per share (-24.9%). At a current spread of $0.93 upside versus$7.74 downside, the implied market probability of deal closing is:

$P_{\text{close}} = \frac{\$31.12 - \$23.38}{\$32.05 - \$23.38} = \frac{\$7.74}{\$8.67} \approx 89.3\%$

An 89.3% market-implied closing probability accurately reflects the low horizontal overlap, but leaves insufficient margin of safety for unhedged accounts at current market prices.

3. Private Equity & Corporate Balance Sheet Strategy

For family offices and private market allocators evaluated in our study on Private Credit Valuation Smoothing and the Diversification Illusion, the CD&R/McKesson hybrid consortium provides a clear structural blueprint. As high-yield corporate credit spreads remain elevated and private credit funds ration capital, private equity sponsors will increasingly partner with investment-grade corporate strategics to co-underwrite acquisitions. This structure eliminates debt execution risk, reduces leverage multiples, and creates a pre-wired liquidity exit for the sponsor via corporate call rights.

---

Conclusion: The New Playbook for High-Rate Healthcare M&A

The acquisition of Option Care Health for $5.8 billion by Clayton, Dubilier & Rice and McKesson marks the formal institutional adoption of the hybrid corporate-sponsor buyout structure in an era of 5.25%+ interest rates.

By disassembling the transaction across the Parallax Six-Factor Framework, institutional investors uncover critical strategic realities:

1. Public market healthcare valuations had compressed into deep Value territory, failing to reflect the non-cyclical, demographic cash-flow stability of home infusion.
2. Synthetic cost-of-capital arbitrage—pairing sponsor equity with corporate balance sheet cash—solves the LBO financing bottleneck without stressing credit ratings.
3. In a 5.28% Treasury yield environment, merger arbitrage spreads must be rigorously stress-tested against risk-free cash yields rather than evaluated on nominal percentage gains.

As third-quarter earnings season approaches and sovereign yields test multi-decade highs, institutional allocators must continuously evaluate their portfolios through multi-factor lenses, identifying where private capital will exploit public market pricing dislocations and systematically rotating out of capped-upside holdings into high-conviction, balance-sheet-resilient compounders.